Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

已完结 20 由 jiopa 发布于 2026/1/9 16:45:15

DOI:10.1200/jco-25-01587
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1200/jco-25-01587

American Society of Clinical Oncology (ASCO)

Abstract：PURPOSE Circulating tumor DNA (ctDNA) is emerging as a promising tool to monitor treatment response in large B-cell lymphoma (LBCL). Tracking tumor-specific phased variants (PVs) allows ult

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierFacile preparation of a multifunctional superhydrophilic PVDF membrane for highly efficient organic dyes and heavy metal ions adsorption and oil/water emulsions separation